Table 1.
Baseline characteristics of colorectal cancer (CRC) patients included in this study (N = 98)
| Characteristics | N (%) | |
|---|---|---|
| Age at diagnosis | Median [IQ range] | 61.6 [55.2–69.9] |
| Gender | Male | 63 (64.3) |
| Female | 35 (35.7) | |
| Stage at diagnosis | II–III | 34 (34.7) |
| IV | 64 (65.3) | |
| (Neo)Adjuvant therapy | No | 72 (73.5) |
| Yes | 26 (26.5) | |
| ECOG PS | 0 | 47 (48.0) |
| 1–2 | 51 (52.0) | |
| Side | Right | 32 (32.7) |
| Transverse | 11 (11.2) | |
| Left | 55 (56.1) | |
| Number of metastatic sites | 1 | 52 (53.1) |
| ≥2 | 46 (46.9) | |
| Surgery for metastatic disease | No | 69 (70.4) |
| Yes | 29 (29.6) | |
| First-line therapy | Chemotherapya | 59 (60.2) |
| Chemotherapy/Cetuximabb | 20 (20.4) | |
| Chemotherapy/Bevacizumabc | 19 (19.4) | |
| Second-line therapy | No | 31 (31.6) |
| Yes | 67 (68.4) | |
| Targeted agent | No | 44 (44.9) |
| Yes (first-line and beyond) | 54 (55.1) |
aFOLFIRI N = 39, FOLFOX N = 20
bFOLFIRI/Cetuximab N = 14, FOLFOX/Cetuximab N = 5, CPT-11/Cetuximab N = 1
cFOLFIRI/Bevacizumab N = 14, FOLFOX/Bevacizumab N = 4, Capecitabine/Bevacizumab N = 1